Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14247942 | 1.00 | ATM (0.38) | ATMHDAC8CMA1CTSKCTSL | |
| SCHEMBL15004669 | 1.00 | ATM (0.38) | ATMHDAC8CMA1CTSKCTSL | |
| SCHEMBL14248130 | 1.00 | ATM (0.38) | ATMHDAC8CMA1CTSKCTSL | |
| SCHEMBL14991009 | 0.92 | HDAC8 (0.36) | HDAC8CTSKCTSLCTSB | |
| SCHEMBL14248329 | 0.92 | HDAC8 (0.36) | HDAC8CTSKCTSLCTSB | |
| SCHEMBL14248282 | 0.92 | HDAC8 (0.36) | HDAC8CTSKCTSLCTSB | |
| SCHEMBL14991008 | 0.92 | HDAC8 (0.36) | HDAC8CTSKCTSLCTSB | |
| SCHEMBL15005791 | 0.92 | HDAC8 (0.36) | HDAC8CTSKCTSLCTSB | |
| SCHEMBL18827805 | 0.89 | ATM (0.38) | ATMHDAC8CMA1CTSKCTSL | |
| SCHEMBL17732635 | 0.82 | ATM (0.37) | ATMHDAC8CMA1CTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721053-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2721053-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2721053-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20130142754-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-06-06 | — | — | US | disclosed |
| US-20130142754-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-06-06 | — | — | US | disclosed |
| WO-2012173983-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012173983-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142754-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | ATM 4436/4885HDAC8 2235/4885CMA1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.